Powered by
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based developer of cholesterol-lowering drugs, announced that the results of a Phase 2 study evaluating the combination of its Nexletol (bempedoic acid) …
ANN ARBOR—Esperion Therapeutics Inc. reported a 150 percent increase in sales for its new cholesterol-lowering drug between the third quarter and the fourth quarter ended Dec. 31. Overall, the company …
CANTON TWP.–MMS Holdings, a contract research organization for the pharmaceutical industry, has joined the Decentralized Trials and Research Alliance, an organization launched in December to unite healthcare companies, regulators, patient …
ANN ARBOR—Esperion Therapeutics Inc., the Ann Arbor developer of novel cholesterol-fighting drugs, announced preliminary financial results and a new licensing agreement with Pittsford, N.Y.-based drug developer Serometrix. “As a result …
ANN ARBOR—Esperion Therapeutics Inc. has named veteran cardiovascular pharmaceutical industry executive Sheldon Koenig as its chief operating officer. Koenig will report to president and CEO Tim M. Mayleben. In this …
ANN ARBOR—Esperion Therapeutics Inc. reported a loss of $85.4 million or $3.07 a share in the third quarter of 2020, vs. a loss of $68.4 million or $2.52 a share …
LANSING—The board of the Michigan Strategic Fund has approved state aid for two business expansions and a community project that will generate a total of $154.7 million in capital investment …
ANN ARBOR–Officials at Esperion Therapeutics Inc. (Nasdaq: ESPR) announced record revenue in the second quarter ended June 30, as its cholesterol-fighting drugs Nexletol and Nexlizet have been approved for use …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a pharmaceutical startup developing new drugs for endocrine diseases, announced that it had engaged SVB Leerink, a Boston-based investment bank, in a “strategic review …
CANTON TWP.—The life sciences regulatory and clinical data consultant MMS Holdings announced it had been retained by Thunder Bay, Ontario-based IGY Life Sciences to further the development of IgY-110, an …